Table 3. IC50 to bortezomib of the panel of sarcoma cell lines used in this study and its correlation to the levels of MAP17 mRNA measured by RT-QPCR.

Cell line	Tumor of origin	IC50 Bortezomib (μM)	MAP17 (2-ΔCT)
93T449	Liposarcoma	35,9±3,75	0,000182199
AA	Leiomyosarcoma	20,65±0,75	6,21882E-05
AW	Liposarcoma	30,95±8,5	0,00011437
AX	Liposarcoma	19,3±5,2	0,000534323
AZ	Fibrosarcoma	92,89±0,92	0,001050201
BC	MPNST	32,5±9,8	0,00025699
BD	Ewing's Sarcoma	149,7±17,42	0,000111012
BG	Myxoid Fibrosarcoma	28,99±5,8	7,64036E-05
BP	Osteosarcoma	502±56,6	2,32244E-05
CE	Rhabdomyosarcoma	15,53±2,9	4,55244E-05
CP0024	Leiomyosarcoma	30,75±5,46	2,84148E-05
CP0038	Leiomyosarcoma	43,65±9,78	2,52213E-05
HT1080	Fibrosarcoma	15,88±2,37	1,68955E-05
Saos-2	Osteosarcoma	52,78±9,5	1,30192E-05
SKUT1	Uterine Leiomyosarcoma	10,95±2,46	4,58532E-05
SW872	Liposarcoma	10,13±2,36	0,000262208

IC50 is the average of 3 independent experiments performed in triplicate. To measure human MAP17 RNA expression, real-time PCR was performed using a ABI 7900HT (Applied Biosystems), and we used GADPH as internal control/reference. Quantitative and statistical analyses of the QPCR data were calculated using Applied Biosystem RQ Manager 1.2.1 software. We presented the 2eΔΔCT data. The levels of MAP17 mRNA presented are the average of the mRNA levels obtained in three independent determinations performed in triplicate samples.